Stakeholders in the pharmaceutical and medical-device development industry are known to adopt a variety of partnership models to collaborate with other companies / organizations. Such deals are inked to not only allow companies to expand their respective product / service portfolios, but also gain additional capabilities in emerging technologies. In the domain of large volume wearable injectors, we identified unique types of partnership deals that were inked between different stakeholders. These include product / technology integration, product development / commercialization, distribution, licensing, merger / acquisition, manufacturing / supply, clinical trial, services agreement and others.
During our research, we found that the number of partnerships has increased steadily between 2015 and 2020. It is important to highlight that the maximum number of deals (25) were signed in 2018. Majority of the deals (7) signed in 2018 were product development and commercialization agreements, followed by 6 distribution agreements. In the first quarter of 2020, 5 partnerships have been inked between various stakeholders.
Product / technology integration agreements account for 29% of the total number of deals inked in the given period of time. It is worth highlighting that 23 out of 25 product / technology integration agreements were inked by insulin delivery device developers, for incorporating advanced features, such as prefilled insulin cartridges, CGM technology, artificial intelligence algorithms and mobile diabetes management platforms, into their insulin pumps. Companies involved in such agreements include (in alphabetical order, no selection criteria) Beta Bionics, Bigfoot Biomedical, Insulet, Medtronic, SFC Fluidics and Ypsomed.
Further, 17% deals were signed for the development of drug device combinations. Majority of the partnerships focused on large volume wearable injectors for delivery of non-insulin drugs, were signed by Enable Injections; notable examples of recent deals include (in reverser chronological order) collaborations with Genentech (August 2019), Sanofi (June 2019) and Apellis Pharmaceuticals (November 2018).
As can be observed in the figure, the companies headquartered in the US have signed 37 agreements with partners based in the same country and 24 agreements with partners based out of the US. Further, Switzerland is another hotspot for the developers of large volume wearable injectors, where companies have inked 13 international partnerships and 4 local partnerships. It is worth mentioning that developers of large volume wearable injectors based in South Korea, France, Japan and Netherlands, have signed international agreements because of the relatively low number of developers of large volume wearable injectors based in Asian countries.
The future market is likely to be driven by the product / technology integration and development agreements inked within companies based in North America.